|
USA-737904-ComputersNetworking Company Direktoryo
|
Company News :
- DYSF gene: MedlinePlus Genetics
The DYSF gene provides instructions for making a protein called dysferlin Learn about this gene and related health conditions
- Dysferlin - Wikipedia
A reduction or absence of dysferlin, termed dysferlinopathy, usually becomes apparent in the third or fourth decade of life and is characterised by weakness and wasting of various voluntary skeletal muscles [11] Pathogenic mutations leading to dysferlinopathy can occur throughout the DYSF gene
- DYSF Gene - GeneCards | DYSF Protein | DYSF Antibody
DYSF (Dysferlin) is a Protein Coding gene Diseases associated with DYSF include Miyoshi Muscular Dystrophy 1 and Myopathy, Distal, With Anterior Tibial Onset Among its related pathways are Cardiac conduction and Smooth Muscle Contraction
- Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and . . .
Dysferlin is a large transmembrane protein involved in critical cellular processes including membrane repair and vesicle fusion Mutations in the dysferlin gene (DYSF) can result in rare forms of muscular dystrophy; Miyoshi myopathy; limb girdle
- Entry - *603009 - DYSFERLIN; DYSF - OMIM - (OMIM. ORG)
Dysf Dmd double-knockout mice developed early-onset cardiomyopathy Han et al (2007) suggested that dysferlin-mediated membrane repair is important for maintaining membrane integrity of cardiomyocytes, particularly under conditions of mechanical stress
- Dysferlinopathy 101 - Jain Foundation
If you or a loved one has been diagnosed with dysferlinopathy, also referred to as LGMD2B, LGMDR2, Miyoshi Myopathy 1, you will have many questions you need answers for and concerns to be addressed Much of the terminology surrounding dysferlinopathy may be confusing
- DYSF | Test catalog | Invitae
Diagnostic testing of this gene is recommended to identify a potential genetic basis for a condition This type of testing can inform prognosis and clinical care for a symptomatic patient or be used to screen unaffected patients (including family members) for increased genetic risk for the condition
- The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism . . .
Dysferlinopathies refer to a spectrum of muscular dystrophies that cause progressive muscle weakness and degeneration They are caused by mutations in the DYSF gene, which encodes the dysferlin protein that is crucial for repairing muscle membranes
- DYSF promotes monocyte activation in atherosclerotic cardiovascular . . .
In conclusion, DYSF promoter hypermethylation upregulated its expression and promoted monocytes activation, which further participated in the pathogenesis of ASCVD
|
|